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Objective and Importance: Malignant pleural effusions occur in the setting of both solid
and hematologic malignancies. Pleural effusion caused by leukemic infiltration is an unusual
extramedullary manifestation of acute myeloid leukemia (AML) with fewer than 20 cases
reported (1–11). We report a case of pericardial and pleural effusions in a patient with AML
and review the literature.
Clinical Presentation: In this case, a 55-year-old man with previous history of myelopro-
liferative neoplasm experienced transformation AML, heralded by appearance of leukemic
pleural effusions. The patient was identified to have leukemic pleural effusion based on
the extended cytogenetic analysis of the pleural fluid, as morphologic analysis alone was
insufficient.
Intervention:The patient was treated with hypomethylator-based and intensive chemother-
apy strategies, both of which maintained resolution of the effusions in the remission
setting.
Conclusion: Due to the rarity of diagnosis of leukemic pleural effusions, both cytogenetic
and fluorescence in situ hybridization testing are recommended. Furthermore, systemic
chemotherapy directed at the AML can lead to complete resolution of leukemic pleural
effusions.
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OBJECTIVE AND IMPORTANCE
Pleural effusion caused by leukemic infiltration is an unusual
extramedullary manifestation of acute myeloid leukemia (AML),
but may be more common than previously thought. Fewer than
20 cases have been reported (1–11). We report a case of pericar-
dial and pleural effusions in a patient with AML and review the
literature.
CASE REPORT: CLINICAL PRESENTATION
A 55-year-old man with polycythemia vera (PV) had pancytope-
nia, moderate pericardial effusion, and bilateral pleural effusions.
He had an 8-year history of PV treated with hydroxyurea and ana-
grelide. He was in his usual state of health until 6 weeks prior to
presentation to our institution when he went to an outside hospital
for a cholecystectomy.
In the weeks following his surgery, he developed nausea
and vomiting, and was found to have a duodenal ulcer and
esophageal erosions. During treatment for these complications,
he was noted to have a moderate-sized pericardial effusion and
pancytopenia. A bone marrow biopsy showed progression of PV
to AML.
He was referred to our institution with shortness of breath,
chest pain, and pancytopenia. Bone marrow biopsy at our institu-
tion confirmed the diagnosis of AML with complex cytogenetics
including trisomy 8, trisomy 9, trisomy 21, and molecular analysis
positive for JAK2 V617F mutation.
The patient had pericardial and exudative pleural effusions
(Figure 1) causing increased oxygen requirement. He under-
went thoracentesis and pericardiocentesis. Work-up for infectious,
rheumatologic, and cardiac causes of the effusions was nega-
tive. Cytology of both effusions revealed reactive mesothelial cells
in a background of acute inflammation, but no malignant cells
were identified. Flow cytometry was done, and the cells in both
the pleural and pericardial fluid were predominantly (70%) of a
phenotype consistent with basophils. Repeat thoracentesis with
cytogenetic analysis was performed. Fluorescent in situ hybridiza-
tion was significant for trisomy 8, trisomy 9, and trisomy 21 in the
pleural effusion. These cytogenetic abnormalities were identical
to the those detected on the presenting bone marrow, and were
found in the majority of the cells analyzed, thereby confirming the
presence of leukemic pleural effusions.
INTERVENTION
The patient was initially treated with decitabine for 5 days. He
had dramatic improvement in performance status during the
hospital stay and then also went on to receive twice-daily fludara-
bine and cytarabine (BIDFA) for an additional 4-day first cycle.
He responded with an approximately 50% reduction of blasts
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FIGURE 1 | Pre-treatment computed tomography (CT) image with
intravenous (IV) contrast, demonstrating bilateral pleural effusions
(white arrows) and moderate-sized pericardial effusion (black arrows),
prior to thoracentesis, pericardiocentesis, or chemotherapy. Black
asterisk= atelectatic lung.
and was given a second cycle of therapy with BIDFA for 4 days.
Complete remission was achieved after the second cycle, but he
developed neutropenic fevers, sepsis, and bacterial endocarditis,
with decreased performance status to 2. In the setting of contin-
ued complete remission but with decreased performance status
and co-morbidities, he was switched to single agent decitabine,
which he tolerated well for four cycles. His performance status
improved back to 1, and imaging continued to demonstrate near
total resolution of effusions in the absence of requiring any fur-
ther thoracenteses (Figure 2). He was being considered for stem
cell transplantation. Unfortunately, the AML ultimately relapsed
prior to stem cell transplant, and the patient died 11 months after
his transformation to AML in the setting of multi-organ failure
and diffused alveolar hemorrhage, although without effusions.
DISCUSSION
Clinically significant pleural effusions, regardless of etiology, are
rarely encountered in patients with AML. A retrospective review
of all patients with acute leukemia, myelodysplastic syndrome
(MDS), or myeloproliferative neoplasm (MPN) who underwent
pleural procedures at our institution from 1997 to 2007 found that
2% (111 patients out of 6,442) required thoracentesis, chest tube
insertion, or pleural catheter placement. Sixty-nine of the patients
had AML; among these, 39 pleural effusions were infectious and 25
were leukemic, determined by positive cytology or flow cytometry
(12). However, the incidence of leukemic pleural effusions may be
increasing as a result of longer survival with improved chemother-
apies (8). In their 10 year review, Faiz et al. noted that the role of
infection was similar to that reported in previous autopsy series,
albeit malignant infiltrative effusions were more frequent than in
earlier series (12). Our review of the literature yielded 13 individual
case reports, summarized in Table 1.
FIGURE 2 | Post-treatment CT image after two cycles of fludarabine
and cytarabine and four cycles of decitabine alone. White
arrow= residual small right pleural effusion. No left pleural effusion or
pericardial effusion. White asterisk= liver.
AML is not a common cause of pleural effusions. A 14-year
study of 5,888 pleural fluid specimens by Johnston et al. found that
10% of the effusions were malignant, of which 15% were attribut-
able to “leukemia” or “lymphoma,” but more specific histopatho-
logic diagnosis were not available (13). A 2-year retrospective
analysis of pleural fluid cytological specimens in India found that
of 898 samples, 164 (18%) were malignant, the majority of hema-
tologic malignancies were Non-Hodgkin’s lymphoma, and none
were AML (14). Similarly, a more recent review of 4,684 con-
secutive pleural fluid specimens received in Turkey found only 1
positive for AML (15).
Other sites of extramedullary leukemia (EML) have been asso-
ciated with FAB M4-M5 subtypes, CD56 (+) blasts, cytogenetic
abnormalities including t(8:21), inversion 16, infant leukemia, 11q
abnormalities, cellular immune dysfunction, and allogeneic stem
cell transplantation. More studies are needed to demonstrate sta-
tistically significant relationships with these variables in patients
with AML pleural effusions. In their review of AML, ALL, and
MDS/MPN collectively, Faiz et al. found that the presence of
pleural effusions did not influence survival but did portend more
aggressive disease if the hematologic malignancy was diagnosed
within 6 months (12).
All the cases described herein occurred concomitantly with or
followed the onset of systemic disease, although in some circum-
stances EML may be discovered prior to the medullary diagnosis.
Still, the timing of the development of a pleural effusion varied
among these cases, from initial presenting symptom to a com-
ponent of progression in patients with refractory disease or as a
harbinger of relapse in patients with marrow remission. Addi-
tionally, as noted before, leukemic pleural effusions can occur
as an isolated finding or in association with parenchymal lung
disease (16).
This case illustrates the importance of cytogenetic analysis on
pleural fluid with fluorescence in situ hybridization (FISH) or
comparative genomic hybridization (CGH) in patients with AML
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Table 1 | Summary of case reports of AML pleural effusion.
Author (Ref.) Sex Age (year) Leukemia status at leukemic
effusion diagnosis
Treatment after diagnosis
of leukemic effusion
Overall outcome
Raynolds (1) M 26 AML Supportive care Death 5 months after diagnosis
Ohe et al. (2) M 51 CD7+AML Induction araC+daunorubicin,
then autologous HSCT
Complete remission for at least
8 months
Park et al. (3) M 41 AML recurrence (31 months
after) HSCT, in BM remission
Not reported Not reported
Khan et al. (4) F 71 AML M5 (acute monocytic
leukemia)
Induction araC+daunorubicin Death 22 days after initiation of
induction chemotherapy
Farray et al. (5) F 45 Acute megakaryoblastic
leukemia (M7)
Not reported Not reported
Fatih (6) M 50 AML M1 3+7 induction
idarubicin+ cytarabine
Effusion resolved, but leukemia was
refractory; death 3 months after
discharge from clinic
Huang (7) F 56 CMMoL with transformation
to AML
3+7 induction
idarubicin+ cytarabine
Respiratory failure; death on
hospital day 64
Stoll (8) M 54 AML–MDS None, ineligible due to renal
function
Home hospice; death 1 week after
discharge
Ou et al. (9) M 53 AML with recurrent genetic
abnormalities
3+7 induction
idarubicin+ cytarabine
Complete remission with first
induction, but effusions did not
resolve. After re-induction with
high-dose cytarabine, effusions
resolved. Later underwent HSCT,
remained disease-free
Chang (10) F 74 AML Induction cytarabine Effusions resolved; complete
remission for at least 11 months
Chang (10) M 75 CMMoL with transformation
to AML
None, ineligible due to poor
performance status
Death 1 month after diagnosis of
pleural myeloid sarcoma
Chang (10) M 74 Refractory AML Supportive care Death 1 month after confirmed
leukemic pleural effusion
Agrawal (11) M 45 AML M2 Induction cytarabine Death 1 week later
HSCT, hematopoietic stem cell transplant; BM, bone marrow; araC, cytarabine; CMMoL, chronic myelomonocytic leukemia.
presenting with pleural effusion (17) to prevent misdiagnosis as
drug toxicity, infection, secondary malignancy, or autoimmune
phenomenon related effusions. Immunohistochemistry is also
helpful (17–20). In addition to their role in diagnosis, cytogenetic
characteristics may change treatment options and prognosis for
subgroups of AML patients.
A recent review suggested that EML is more common than
previously thought, and that routine baseline pre-treatment imag-
ing studies with PET/CT may be warranted to help establish
the true incidence of EML (21). Additionally, any patient with
AML presenting with a pleural effusion should routinely undergo
cytogenetic evaluation as a part of the pleural fluid analysis.
Further studies are warranted to elucidate the prognostic sig-
nificance of AML pleural effusions and on the safety and efficacy
of newer targeted therapies. Success has been reported with stan-
dard induction chemotherapy, stem cell transplant, and as with
our case presentation, with hypomethylating agent decitabine as
therapeutic options for patients with such unique presentations.
CONCLUSION
Leukemic effusions are rare but the incidence may be under-
estimated. Patients with AML presenting with a pleural effu-
sion should receive cytogenetic studies as a routine part of the
pleural fluid analysis. Systemic chemotherapy has yielded success-
ful results with resolution of effusions and complete remission.
Further prospective studies are warranted to better characterize
the incidence and outcomes of leukemic pleural and pericardial
effusions from AML.
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